[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572562":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":39,"responsibleParty":58,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":11,"enrollmentInfo":74,"targetDuration":11,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":88,"whyStopped":11,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University Hospital, Lille","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Benralizumab","EXPERIMENTAL",null,[13],"Drug: Benralizumab 30 MG\u002FML [Fasenra]",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Benralizumab 30 MG\u002FML [Fasenra]","Subcutaneous injection 30 mg at day 2, week 4 and week 8.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride","Subcutaneous injection at day 2, week 4 and week 8",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Delphine STAUMONT-SALLE, Professor, MD","CONTACT","+33320444145","DRC@chu-lille.fr",{"name":36,"role":32,"phone":33,"phoneExt":37,"email":38},"Japhete ELENGA KOANGA","30939","japhete.elengakoanga@chu-lille.fr",[40],{"facility":41,"status":11,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Delphine STAUMONT-SALLE","Lille","Nord","59000","France","FR",{"type":48,"coordinates":49},"Point",[50,51],3.05512,50.63391,{"lat":51,"lon":50},[54,56],{"name":55,"role":32,"phone":33,"phoneExt":11,"email":34},"Delphine STAUMONT-SALLE, MD, Professor",{"name":55,"role":57,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":59,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[61],{"name":62,"class":63},"AstraZeneca","INDUSTRY","100572562","phase-2-interest-of-a-targeted-therapy-for-the-treatment-of-a-severe-form-of-hypersensitivity-to-drug-dress-syndrome-100572562",false,"NCT06734884","Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)","Efficacy and Safety of Anti-interleukin 5 Receptor Therapy (Benralizumab) in Patients With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)","BENRADRESS","Inclusion Criteria:\n\n1. Adult patients (minimum 18year-old)\n2. diagnosed at D0 (= baseline and inclusion) with DRESS defined by:\n\n   1. with a REGIScar score at D0 calculated at at least 4 (4 or 5: probable DRESS; \\>5: definite case of DRESS), see Annex: REGIScar criteria\n   2. Skin eruption with an onset considered as compatible with a DRESS syndrome according to the investigator's opinion after the uptake of one or several drug(s)\n   3. AND Fever ≥ 38°C at the time of the examination or notion of a thermal peak ≥ 38°C in the preceding 72 hours.\n   4. At least 1 organ disorder compatible with the diagnosis of DRESS syndrome among the following disorders:\n\n      * Adenopathies present in at least 2 different sites and ≥ 1 cm in size\n      * Acute hepatitis defined by :\n\n        * Elevation of liver enzymes in serum: ALAT (Alanine Aminotransferase) and\u002For ASAT (Aspartate Aminotransferase)\n        * AND\u002FOR an increase in serum total bilirubin, according to the standards of the local analysis laboratory (in the absence of a history of liver disease: ASAT and\u002For ALAT ≥ 3N (=3 times normal)\n        * AND\u002FOR total bilirubin ≥ 2N\n      * Acute renal failure defined by :\n\n        * An increase in creatinine according to local laboratory standards\n        * AND a sterile cytobacteriological examination (in the absence of a history of renal disease: creatininaemia ≥ 1.5N\n        * AND\u002FOR increase in creatinine ≥ 0.3 mg\u002Fdl (or ≥ 26.5 mol\u002FL)\n        * AND\u002FOR urine output \\< 0.3 ml\u002Fkg\u002Fh (over ≥ 24h).\n      * Pulmonary impairment defined by:\n\n        * Oxygen saturation (SpO2) measured by pulse oximetry ≤ 95% in room air\n        * And\u002For the presence of an interstitial syndrome on a standard chest X-ray or a CT scan of the chest (in the absence of any other cause of lung damage).\n3. With eosinophilia (blood eosinophil count ≥ 500\u002Fmm3 or ≥0.5 G\u002FL).\n4. Patient having given written informed consent\n5. patient with social insurance\n\nExclusion Criteria:\n\n1. Patients \\<18 year-old\n2. Patients with DRESS with REGIScar score \\<4\n3. Patients without skin eruption at baseline\n4. Eosinophils blood count \\<500\u002Fmm3 or \\< 0.5 G\u002FL at baseline\n5. Patients with contra-indication to blood samples dedicated to the biocollection, according to the investigator's opinion\n6. Patients with contra-indication to stop the culprit drug(s) involved in DRESS\n7. Past history of hypersensitivity to biological drugs\n8. Patients who received a previous anti-IL5 or anti-IL5 receptor therapy within 5 half lives (= 4 months) before inclusion\n9. Patients with a contra-indication of topical corticosteroids (mainly a past history of contact eczema with clobetasol propionate)\n10. Pregnancy and lactation","ALL","18 Years",{"count":75,"type":76},96,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","Drug Reaction with eosinophilia and Systemic Symptoms (DRESS) is a rare and severe multiorgan drug reaction whose pathophysiological mechanisms underlying remain unclear, but may involve the role of several immune cells like eosinophils. iIndeed,the number of eosinophils is increased in blood and\u002For in organs tiisues in at least 50% of patients with DRESS. There is no specific treatment available. The standard of care is corticosteroids, but they may be inefficient or poorly tolerated. The aim of this research is to find out whether a specific treatment of the immunological response in DRESS syndrome would be useful in combination with corticosteroids to speed up the recovery from DRESS syndrome and therefore reduce the total length of your hospital stay when your illness is being managed. This a multicenter, international, prospective, interventional study, double-blinded, placebo-controlled, randomized, in two balanced parallel groups, one receiving the standard of care (topical or systemic corticosteroids, according to the severity of DRESS syndrome) and the other one corticsoteroids and a targeted therapy against eosinophils (benralizumab, already available in other eosinophilic diseases like asthma).",[82],"DRESS Syndrome",[84,85,86,9,87],"DRESS syndrome","drug hypersensitivity","Eosinophil","targeted therapy","NOT_YET_RECRUITING","2026-05-14",{"date":91,"type":92},"2026-05-15","ACTUAL",{"date":94,"type":76},"2027-01-06",{"date":96,"type":76},"2029-09-01",{"name":5,"class":6},1]